GlassScriptPhysician profile
Billy Ray Price
NPI 1841369949
$5,544.31
in general payments reported to CMS, 2019-2025
46 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $433 · 2021: $435 · 2022: $764 · 2023: $1,181 · 2024: $1,068 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $790.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $470.00 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $386.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.47 | 2019-2025 | Jardiance |
| Abbvie INC. | $351.38 | 2021-2025 | |
| Glaxosmithkline, LLC. | $346.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $334.73 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $275.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $239.81 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $211.58 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $197.49 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $179.95 | 2019-2024 | Gardasil 9, Vaxneuvance, Proquad |
| Corium, LLC | $111.10 | 2023-2025 | Azstarys |
| Sanofi Pasteur INC. | $110.06 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.20 | 2023-2025 | Caplyta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.